Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma

Giorgio Scagliotti

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial evaluating the combination of chemotherapy and gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), as first-line treatment for patients with advanced lung adenocarcinoma and activating EGFR mutations.

Share this video  
Similar topics
Related videos
1:39
Immunotherapy: key messages from MASCC 2016
Bernardo Rapoport
1:05
What's next for Merkel cell carcinoma trials
Isaac Brownell
2:48
Olanzapine for nausea control in chemotherapy-treated patients
Charles Loprinzi
2:11
Treatment options for patients with bladder cancer, is bladder removal always necessary?
Alison Birtle
2:43
Clinical factors in the selection of patients for first-line immunotherapy of lung cancer
Benjamin Besse
Lung Cancer
Gefitinib
ELCC 2016
Interview
15th April 2016
More from Giorgio Scagliotti
ASCEND-1 and ASCEND-2: Ceritinib for ALK-rearranged NSCLC and baseline brain metastases
Phase 2 trial of BI 1482694 (HM61713), third-generation TKI, in T790M-positive NSCLC
Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJOncology is intended for healthcare professionals